AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate

AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
The post AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate appeared first on The Motley Fool Australia. –

woman waering face mask holding vial of covid-19 vaccine

The Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.  

According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following further analysis with an additional 49 symptomatic COVID-19 cases.

Details of the COVID-19 vaccine findings

After scrutiny from the US National Institute of Allergy and Infectious Diseases for purportedly out-of-date data in the original phase 3 preliminary study, AstraZeneca conducted a fuller analysis to lay any claims to rest.

The findings, which were published yesterday, included 32,449 participants. Of those participants, 190 were symptomatic with COVID-19. This provided the drug developer an additional 49 cases compared to its original analysis.

Following the double-blind placebo study, AstraZeneca found its vaccine to have an efficacy of 76% rather than the previous 79%. Notably, the vaccine was found to have a 100% efficacy against severe or critical disease and hospitalisation. Furthermore, for individuals aged 65 years or older, the vaccine proved to be 85% effective.

Perhaps most importantly, considering the swarm of allegations, the vaccine was well tolerated, and no safety concerns related to the vaccine were identified.

Commenting on the further substantiated results, Executive Vice President Mere Pangalos stated:

The primary analysis is consistent with our previously released interim analysis and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over. We look forward to filing our regulatory submission for Emergency Use Authorization in the US and preparing for the rollout of millions of doses across America.

Australia’s AstraZeneca rollout in progress

The COVID-19 vaccine rollout continues in Australia. On Monday the government commenced phase 1B of the rollout. Phase 1B includes the following priority groups:

  • Elderly adults aged 80 years and over
  • Elderly adults aged 70 years and over
  • Health care workers not vaccinated in phase 1A
  • Aboriginal and Torres Strait Islander adults over 55
  • Adults with a specified medical condition
  • Adults with a severe disability who have a specified underlying medical condition
  • Critical and high-risk workers including defence, police, fire, emergency services, and meat processing

The AstraZeneca vaccine was also recently approved by the Therapeutic Goods Administration (TGA) for local production by CSL Ltd (ASX: CSL) in Melbourne.

The biopharmaceutical giant sent out its first batch on Wednesday morning, containing 832,200 doses. Production is expected to ramp up as the company targets 50 million doses by the end of the year.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!